Section Arrow
Quote
NUVB.NYSE
- Nuvation Bio
Quotes are at least 15-min delayed:2026/03/23 05:29 EDT
Pre Market
Last
 4.1
-0.12 (-2.84%)
Bid
4.05
Ask
4.22
High 4.13 
Low 4.09 
Volume 869 
Regular Hours (Closed)
Last
 4.22
-0.04 (-0.94%)
Day High 
4.376 
Prev. Close
4.26 
1-M High
5.92 
Volume 
7.28M 
Bid
4.05
Ask
4.22
Day Low
4.15 
Open
4.26 
1-M Low
4.125 
Market Cap 
1.46B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.49 
20-SMA 4.91 
50-SMA 5.6 
52-W High 9.75 
52-W Low 1.54 
Exchange NYSE 
Valuation Estimation
EPS (Current/Estimated)
-0.60/-0.36
Enterprise Value
1.51B
Balance Sheet
Book Value Per Share
0.88
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
62.90M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
AZTRAzitra0.2828+0.1067+60.59%-- 
Pre Market 0.2584 -0.0244 -8.63%
LNAILunai Bioworks Inc.0.4685+0.0835+21.69%-- 
Pre Market 0.4425 -0.026 -5.55%
DRMADermata Therapeutics Inc1.46+0.25+20.66%0.09PE
Pre Market 1.35 -0.11 -7.53%
GERNGeron Corp1.46-0.09-5.81%-- 
Pre Market 1.44 -0.02 -1.37%
IBRXImmunityBio8.47-0.35-3.97%-- 
Pre Market 8.49 +0.02 +0.24%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.